

Paxlovid™ is an antiviral drug to treat **mild COVID-19** in people who have **tested positive** and have **symptoms**.

- Paxlovid™ prevents hospitalization and death in people who are at **high risk** of serious illness from COVID-19.
- **Paxlovid™ does not seem to help people without risk factors.** People without risk factors:
 - are unlikely to be hospitalized or die from COVID-19.
 - tend to recover without needing an antiviral medicine like Paxlovid™.
 - should be reassured that they do not need Paxlovid™ and offered symptom management.
- Paxlovid may cause side effects and has many potential drug interactions.

ELIGIBILITY CRITERIA: Individuals must meet ONE of the criteria.

Moderately to severely immunocompromised people are eligible regardless of age (≥18 years), vaccination status, and other risk factors. This includes:

- Active treatment for cancer*
- Solid organ transplant recipient*
- Stem cell transplant recipient*
- Moderate or severe primary immunodeficiency* (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Immunocompromised due to medications



Conditions other than those listed here do not meet the definition of moderately to severely immunocompromised for Paxlovid™ prescribing. Consider other risk factors.

*Refer to appropriate specialist for Paxlovid™ prescribing – Cancer Clinic, Transplant Clinic, or Early COVID Therapeutics Team

UNVACCINATED/UNDER-VACCINATED

=received no doses or 1 dose of a 2-dose vaccine AND

- Age >55 years
- Age ≥18 years to <55 years with 1 or more risk factors

VACCINATED

=received 2 or more doses of a 2-dose vaccine or 1 dose of Janssen Jcovden™ AND

- Age ≥70 years with 3 or more risk factors
- Age ≥70 years AND Indigenous with 2 or more risk factors
- Age ≥70 years AND residing in the North (NE1/2, NW 1, AHA) with 2 or more risk factors

Vaccination provides protection against hospitalization and death. People who are vaccinated may not need Paxlovid™ unless they have other risk factors.

RISK FACTORS:

Total #: _____

- Body Mass Index (BMI) ≥30 kg/m²
- Chronic kidney disease (eGFR ≥30mL/min to <60mL/min)
- Cardiovascular or cerebrovascular disease (hypertension, coronary artery disease, congestive heart failure, congenital heart disease, cardiomyopathy, atrial fibrillation, hyperlipidemia, stroke)
- Chronic lung disease (COPD, moderate to severe asthma, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension)
- Diabetes—Type 1 or 2
- Neurodevelopmental disorders (e.g., cerebral palsy, Down syndrome) or other conditions that confer medical complexity (i.e., genetic or metabolic syndromes and severe congenital anomalies)
- Sickle cell disease

CONTRAINDICATIONS AND CAUTIONS:

- Hypersensitivity to nirmatrelvir, ritonavir, or any other components of the product
- Longer than day 5 of symptoms but less than day 7
- HIV and not currently on antiretroviral therapy or recent detectable viral load, AIDS-defining illness, CD4 count <200 mm³, or suspicion of uncontrolled HIV
- eGFR <30 mL/min
- Unmanageable drug interaction with nirmatrelvir/ritonavir

May be eligible for remdesivir
→ Refer to Early COVID Therapeutics Team

- Symptoms of moderate to severe COVID-19
- Previous COVID-19 infection and less than 90 days since symptoms have resolved
- Longer than 7 days since symptom onset
- Previously received 2 courses of early COVID-19 antiviral (Paxlovid™, remdesivir)
- Age <18 years old
- Pregnant, breastfeeding, or unwilling to use effective contraception/abstinence while on therapy
- Liver disease with severe hepatic impairment
- Drug interaction with hydroxychloroquine/chloroquine, and/or strong inducers of CYP3A4 and p-glycoprotein

Not eligible for early COVID-19 antiviral →
Emergency refer if needed +/- supportive care and symptom management